U.S. Stock Market Movement: Definium surged on September 28 due to DT120 Phase III positive results and expected listing application

Definium September 28th Surge Interpretation

Keywords: DT120 Phase III Positive Results, Listing Application Expectation

1. On September 14, the company announced that the Panorama study of DT120 for generalized anxiety disorder reached its primary endpoint and all key secondary endpoints; at week 12, the 100-microgram dose showed a 5.1-point improvement in placebo-adjusted HAM-A, p<0.0001, effect size d=0.64, and no new safety signals were observed.

2. On September 8, DT120 was granted Breakthrough Therapy Designation for major depressive disorder; on September 14, the company stated it plans to conduct pre-marketing discussions with regulatory authorities in Q4 2026 and submit a listing application covering relevant indications in the first half of 2027.

3. On September 24, the company’s relevant clinical data showed that DT120 achieved statistically significant improvement with a single treatment in phase III trials for both generalized anxiety disorder and major depressive disorder; the company focuses on developing next-generation therapies for psychiatric and neurological diseases, with core candidate products including DT120 and DT402.

(Disclaimer: This content is generated by AI technology summarizing publicly available information and is for reference only. It does not constitute investment advice.)